Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Cystic Fibrosis
Sort By
Newest First
1 / 1
1 / 1
Cystic Fibrosis
Spirovant Sciences Doses First Patient in Phase 1/2 Trial of Its Aerosol-Delivered Genetic Medicine for Treating Cystic Fibrosis
Spirovant Sciences
PR-11-24-NI-101
Nov 15, 2024
Cystic Fibrosis
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
Aridis Pharmaceuticals, Inc.
PR-M12-18-NI-013
Dec 05, 2018
FDA Approval
FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene
Vertex
PR-M09-18-NI-050
Sep 19, 2018
FDA Approval
FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease
Vertex
PR-M08-18-NI-075
Aug 20, 2018
Partnership
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Announce New Partnership
Boehringer Ingelheim
PR-M08-18-NI-049
Aug 13, 2018
